ketoconazole has been researched along with Cholestasis in 7 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Cholestasis: Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cholestasis is a DILI that results from impairment of bile acid transporters, such as the bile salt export pump (BSEP), leading to accumulation of bile acids." | 1.51 | Changes in Bile Acid Concentrations after Administration of Ketoconazole or Rifampicin to Chimeric Mice with Humanized Liver. ( Fujino, C; Ishida, Y; Kisoh, K; Kotake, Y; Ohta, S; Sanoh, S; Sugahara, G; Tamura, Y; Tateno, C; Yanagi, A; Yoshizane, Y, 2019) |
| "Cholestasis is one of the major causes of drug-induced liver injury (DILI), which can result in withdrawal of approved drugs from the market." | 1.46 | Mechanism-based risk assessment strategy for drug-induced cholestasis using the transcriptional benchmark dose derived by toxicogenomics. ( Honda, H; Ito, Y; Kawamoto, T; Morita, O, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dawson, S | 1 |
| Stahl, S | 1 |
| Paul, N | 1 |
| Barber, J | 1 |
| Kenna, JG | 1 |
| Kawamoto, T | 1 |
| Ito, Y | 1 |
| Morita, O | 1 |
| Honda, H | 1 |
| Ali, I | 1 |
| Khalid, S | 1 |
| Stieger, B | 1 |
| Brouwer, KLR | 1 |
| Sanoh, S | 1 |
| Tamura, Y | 1 |
| Fujino, C | 1 |
| Sugahara, G | 1 |
| Yoshizane, Y | 1 |
| Yanagi, A | 1 |
| Kisoh, K | 1 |
| Ishida, Y | 1 |
| Tateno, C | 1 |
| Ohta, S | 1 |
| Kotake, Y | 1 |
| Kolts, BE | 1 |
| Langfitt, M | 1 |
| Benson, GD | 1 |
| Anderson, PK | 1 |
| Combes, B | 1 |
| Ishak, KG | 1 |
| Stricker, BH | 1 |
| Blok, AP | 1 |
| Bronkhorst, FB | 1 |
| Van Parys, GE | 1 |
| Desmet, VJ | 1 |
7 other studies available for ketoconazole and Cholestasis
| Article | Year |
|---|---|
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Mechanism-based risk assessment strategy for drug-induced cholestasis using the transcriptional benchmark dose derived by toxicogenomics.
Topics: Administration, Oral; Animals; Chlorpromazine; Cholestasis; Cholesterol; Cyclosporine; Diclofenac; D | 2017 |
Effect of a Common Genetic Variant (p.V444A) in the Bile Salt Export Pump on the Inhibition of Bile Acid Transport by Cholestatic Medications.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; Baculoviridae; Bile Acids and Sal | 2019 |
Changes in Bile Acid Concentrations after Administration of Ketoconazole or Rifampicin to Chimeric Mice with Humanized Liver.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Bile Acids and Sal | 2019 |
Drugs and the liver.
Topics: Acetaminophen; Adult; Aspirin; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liv | 1984 |
Prolonged jaundice following ketoconazole-induced hepatic injury.
Topics: Adult; Biopsy; Cholestasis; Humans; Hyperbilirubinemia; Ketoconazole; Liver; Male; Middle Aged; Pred | 1988 |
Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases.
Topics: Biopsy; Chemical and Drug Induced Liver Injury; Cholestasis; Female; Humans; Ketoconazole; Liver; Ma | 1986 |